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We assessed the presence of vascular endothelial growth factor (VEGF)-C, VEGF-D and their receptor VEGFR-3 by
immunohistochemistry in 59 epithelial ovarian carcinomas, 11 borderline tumours and 20 benign cystadenomas. VEGF-C and
VEGF-D were generally expressed in tumour cells and also in endothelia adjacent to tumour nests which showed a strong staining for
them. VEGFR-3 was expressed in lymphatic and vascular endothelial cells adjacent to tumour nests. Immunoreactivity was significantly
more frequent as lesions progressed from a benign tumour to advanced carcinoma. A strong correlation was found between VEGF-C
and VEGF-D detected in carcinoma and VEGFR-3 detected in neighbouring endothelial cells. Increased expression of VEGF-C, VEGF-
D and VEGFR-3 was significantly associated with lymph node metastasis and peritoneal metastasis outside the pelvis. There was a
significant correlation between the high levels of VEGF-C and VEGF-D proteins, and poor survival. The presence of VEGF-D was an
independent prognostic indicator by multivariate analysis. We conclude that VEGF-C, VEGF-D and VEGFR-3 play an important role
in lymphatic spread and intraperitoneal tumour development in ovarian carcinoma. Since VEGF-D was found to be an independent
predictor of poor outcome, its measurement, together with other prognostic markers may improve prospective identification of
patients with a poor prognosis.
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Survival rates for patients with epithelial ovarian carcinoma have
shown modest improvement in the past decade, but remain
unsatisfactory (Yokoyama et al, 1999). Ovarian carcinoma has the
highest mortality rate among gynaecological malignancies. When
the disease is limited to the ovaries, the 5-year survival rate is more
than 90%, whereas when it has extended to the intra-abdominal or
retroperitoneal cavity, the survival rate decreases to only 30%
(Greenlee et al, 2000). Established prognostic parameters for
epithelial ovarian carcinomas include surgical staging, histological
subtype, grading, lymph node metastasis and residual tumour after
cytoreductive surgery (Yokoyama et al, 1999), but there is a lack of
clinically reliable molecular markers for assessing prognosis in
ovarian carcinoma. Thus, it is urgently required to identify
additional prognostic parameters and to clarify the mechanism
by which tumour spreads from the ovaries to distant sites.
It is well established that angiogenesis, the formation of new
blood vessels, is necessary for the growth and metastatic spread of
solid tumours (Folkman, 1990). Tumour progression is regulated
by numerous stimulators and inhibitors of tumour angiogenesis
(Folkman, 1995). Among angiogenic stimulators, vascular en-
dothelial growth factor (VEGF)-A plays essential roles in
vasculogenesis and angiogenesis (Beck and D’Amore, 1997), and
plays a crucial role in tumour angiogenesis in a variety of
carcinomas (Ellis and Fidler, 1996). However, the significant roles
of other VEGF family members, VEGF-B, VEGF-C, VEGF-D and
placenta growth factor (PLGF) in tumour angiogenesis and
metastasis are not fully known (Nicosia, 1998).
VEGF-C stimulates the proliferation of both vascular and
lymphatic endothelial cells in vitro (Joukov et al, 1997; Pepper
et al, 1998), and promotes angiogenesis or hyperplasia of
lymphatic vessels in vivo (Jeltsch et al, 1997; Cao et al, 1998;
Witzenbichler et al, 1998) via VEGF receptor (VEGFR)-2 (KDR)
and VEGFR-3 (Flt-4). VEGFR-2 is predominantly expressed by
activated endothelia of blood vessels (Joukov et al, 1996; Neufeld
et al, 1999) and VEGFR-3 is predominantly expressed by lymphatic
endothelia (Kaipainen et al, 1995; Jussila et al, 1998). Increased
levels of VEGFR-3 have been detected in lymphatic endothelia
adjacent to carcinoma cells and in lymph nodes containing
carcinoma metastases (Kaipainen et al, 1995; Jussila et al, 1998).
VEGF-D, known as c-fos-induced growth factor (Orlandini et al,
1996), also binds to and activates VEGFR-2 and VEGFR-3 (Achen
et al, 1998; Baldwin et al, 2001), suggesting a role for VEGF-D in
tumour angiogenesis and lymphangiogenesis. Recent work has
provided direct evidence that VEGF-C and VEGF-D are not only
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also enhance lymphatic metastasis in mouse tumour models
(Mandriota et al, 2001; Skobe et al, 2001; Stacker et al 2001). A
soluble form of VEGFR-3 has been found to be a potent inhibitor
of VEGF-C and VEGF-D signalling when expressed in the skin of
transgenic mice (Makinen et al, 2001).
Identification of a correlation between the presence of VEGF-C
and VEGF-D and patient survival as well as lymphatic metastasis
in different carcinoma types might lead to a novel therapeutic
approach to prevent tumour progression in many carcinomas.
In this retrospective study, we assessed the presence of VEGF-C,
VEGF-D and VEGFR-3 in benign tumours, borderline tumours and
carcinomas of the ovary by immunohistochemistry. We deter-
mined their relation to known prognostic factors for ovarian
carcinoma.
MATERIALS AND METHODS
Study population and tissues
Immunohistochemical examination was performed retrospectively
on 90 epithelial ovarian tumours obtained from women who were
surgically treated at the Hirosaki University Hospital between 1989
and 2000 after informed consent had been obtained. The tissue
specimens included 59 epithelial ovarian carcinomas, 11 border-
line tumours and 20 benign cystadenomas. All patients with
epithelial ovarian carcinoma were surgically staged in accordance
with the 1988 International Federation of Gynaecology and
Obstetrics (FIGO) criteria. Namely, they underwent total hyster-
ectomy, bilateral salpingo-oophorectomy, partial omentectomy,
appendectomy, and pelvic and para-aortic lymphadenectomies.
Patients included in this study had not received any preoperative
chemotherapy. The breakdown for stages of ovarian carcinomas
consisted of 27 patients with stage I, six with stage II, 19 with stage
III and seven with stage IV. Histological types were classified into
32 cases with serous cystadenocarcinoma, seven with mucinous
cystadenocarcinoma, 12 with endometrioid adenocarcinoma, six
with clear cell adenocarcinoma, and two with undifferentiated
adenocarcinoma. All cases were re-evaluated for histological type
and grade by the same gynaecological pathologist (SS). All patients
with ovarian carcinoma received postoperative chemotherapy
combining cisplatin (60mgm
 2), epirubicin (40mgm
 2) and
cyclophosphamide (300mgm
 2). The duration of follow-up
ranged from 8 to 156 months (median, 54 months). During that
median follow-up period, there were 20 carcinoma-specific deaths.
The mean age of patients with ovarian carcinoma at surgery was
54.1 years (range, 28–78 years). Of the 11 borderline tumours, six
were serous, and five mucinous. Of the 20 benign cystadenomas, 12
were serous, and eight mucinous. Patients with benign or
borderline tumours did not receive any postoperative chemo-
therapy and all of them remained alive at the end of the study.
Immunohistochemistry
Goat polyclonal anti-VEGF-C (Cat No. AF752), anti-VEGF-D (Cat
No. AF286) and anti-VEGFR-3 (Cat No. AF349) antibodies were
purchased from R&D Systems (Abingdon, UK). Anti-VEGF-C,
anti-VEGF-D and anti-VEGFR-3 antibodies were used at a
concentration of 5, 5 and 1mgml
 1, respectively. All samples
surgically obtained for immunohistochemistry were immediately
fixed in formaldehyde and embedded in paraffin wax. Tissue
sections (6mm) were passed through xylene and graded alcohols.
Sections were placed in 0.01 M citrate buffer, pH 6.0, and heated at
800W in a microwave oven for 5min to retrieve tissue antigen. The
sections were treated with 0.3% hydrogen peroxide (H2O2)i n
methanol for 10min to quench the endogenous peroxidase activity
within the tissue. Nonspecific binding sites were blocked with 1%
BSA and 20% heat-inactivated rabbit serum in phosphate-buffered
saline (PBS) for 30min at room temperature (RT). The sections
were incubated overnight at 41C in the presence of the primary
antibody. Then slides were washed (three changes over 1h) in PBS
containing 0.1% Tween 20 (PBS/Tween), before the application of
the secondary biotinylated antibody (DAKO, Kyoto, Japan). Tissue
was incubated with secondary antibody for 1h at RT before being
washed for 15min with three changes of PBS/Tween. The sections
were then incubated for 30min with avidin-biotinylated–horse-
radish peroxidase complex (Vectastain Elite ABC kit, Vector Lab.,
Peterborough, UK) and reactivity visualised with 0.02% 3,30-
diaminobenzidine tetrahydrochloride (DAB, Sigma) as a chromo-
gen in Tris-HCl buffer (pH 7.6) containing 0.03% H2O2. The
sections were counterstained with Mayer’s Haemalum. For each
antibody, negative control studies were performed in which
normal goat serum was used instead of the primary antibody.
No significant staining was observed in the negative control
sections. As positive controls, formalin-fixed paraffin-embedded
sections from normal human placenta were stained for VEGF-C
and VEGF-D, and paraffin sections from human endometrial
adenocarcinoma known to express VEGFR-3 (Yokoyama et al,
2000) were stained by the same procedure. Two observers
independently evaluated and interpreted the results of immuno-
histochemical staining, without knowledge of the clinical data of
each patient. VEGF-C and VEGF-D staining were assessed by
estimating the percentage of tumour cells in which staining was as
intense as that of positive control cells or more intense than it and
placing tumours into four groups:  (0%), negative; 7(o10%),
weak; +(10–50%), moderate; ++(450%), strong. Faint or equivo-
cal immunoreaction was ignored. Tumours were considered
positive when they showed moderate or strong staining for
VEGF-C and VEGF-D (Umemoto et al, 2001). Regarding VEGFR-
3 staining, cases in which at least 5% of endothelial cells adjacent
to tumour nests were as strongly immunoreactive as positive
control cells were considered positive (Kajita et al, 2001). We also
carried out immunostaining on the serial sections using anti-CD31
antibody (R&D Systems, Abingdon, UK, Cat No. BBA7) to
Table 1 Detection of VEGF-C, VEGF-D and VEGFR-3 in ovarian tumours
VEGF-C detection (%) VEGF-D detection (%) VEGFR-3 detection (EC) (%)
Tissues No. of patients 0 o10% 10–50% 450% 0 o10% 10–50% 450% Negative Positive
Benign tumour 20 12 (60.0) 8 (40.0) 0 0 14 (70.0) 6 (30.0) 0 0 18 (90.0) 2 (10.0)
Borderline tumour 11 4 (36.4) 5 (45.4) 2 (18.2) 0 6 (54.5) 3 (27.3) 2 (18.2) 0 8 (72.7) 3 (27.3)
Carcinoma 59 0 20 (33.9) 17 (28.8) 22 (37.3) 4 (6.8) 18 (30.5) 22 (37.3) 15 (25.4) 25 (42.4) 34 (57.6)
The incidence of VEGF-C and VEGF-D detected in carcinomas was significantly higher than that detected in benign tumours (Mann–Whitney U-test, Po0.0001, respectively)
and borderline tumours (Mann–Whitney U-test, P=0.0002 and 0.0007, respectively). The frequency of VEGFR-3 detected in carcinomas was significantly higher than that
detected in benign tumours (w
2, Po0.0002) and high with a marginal significance compared to that detected in borderline tumours (w
2, P=0.06). There was no significant
difference in the levels of VEGF-C, VEGF-D and VEGFR-3 positivity between samples of benign and borderline tumours.
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British Journal of Cancer (2003) 88(2), 237–244 & 2003 Cancer Research UKdistinguish lymphatic from vascular endothelium. We detected
VEGFR-3 expression on both lymphatic and vascular endothelia
neighbouring tumour nests.
Statistical analysis
The statistical significance of the relation between detection of
VEGF-C, VEGF-D and VEGFR-3 and clinico-pathological factors
was evaluated with univariate analysis using w
2 test and Fisher’s
exact probability test. Carcinoma-specific survival rates were
calculated by the Kaplan–Meier method, and the statistical
significance of differences in the cumulative survival curves
between the groups was evaluated by the log-rank test. Multi-
variate survival analysis was performed using Cox’s propor tional
hazard method. Other statistical analysis was carried out using the
Mann–Whitney U-test. A result was deemed significant at Po0.05.
Figure 1 Immunohistochemical staining of VEGF-D in ovarian tumours and positive control. (A) Positive control in placental vessel and villi (scale bar,
25mm). (B) Negative staining in benign cystadenoma (scale bar, 25mm). (C, D, E, and F)  : negative, 7: weak, +: moderate, ++: strong, respectively, in
epithelial ovarian carcinoma tissues (scale bar in C and D: 25mm, scale bar in E and F: 50mm). Arrows in F show VEGF-D-positive lymphatic and vascular
endothelia adjacent to the carcinoma.
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British Journal of Cancer (2003) 88(2), 237–244 & 2003 Cancer Research UKRESULTS
Detection of VEGF-C and VEGF-D in ovarian tumours, and
detection of VEGFR-3 in endothelial cells adjacent to
tumour nests
The frequencies of detection of VEGF-C and VEGF-D in ovarian
tumours and those of VEGFR-3 in endothelial cells adjacent to
tumour nests are demonstrated in Table 1. In benign tumours,
tumour cells failed to stain or showed very weak staining for
VEGF-C and VEGF-D. Approximately 80% of borderline tumours
failed to stain or showed weak staining for VEGF-C and VEGF-D,
while a few cases showed moderate staining. Correspondingly, 90
and 72% of benign and borderline tumours failed to stain for
VEGFR-3 in endothelial cells adjacent to tumour cells, respectively.
In ovarian carcinomas, 66 and 63% of cases showed moderate or
strong staining for VEGF-C and VEGF-D, respectively. In all, 57%
of ovarian carcinomas stained positively for VEGFR-3 in
endothelial cells adjacent to the carcinoma.
There was no significant difference in the levels of VEGF-C,
VEGF-D and VEGFR-3 positivity between samples of benign and
borderline tumours (Table 1). The incidence of VEGF-C and
VEGF-D detected in ovarian carcinomas was significantly higher
than that detected in benign tumours (Table 1, Po0.0001,
respectively) and borderline tumours (Table 1, P¼0.0002 and
0.0007, respectively). Similarly, the frequency of VEGFR-3 detected
in ovarian carcinomas was significantly higher than that detected
in benign tumours (Table 1, Po0.0002). VEGF-C and VEGF-D
were, in general, homogeneously stained in the cytoplasm of
tumour cells in positive cases (Figure 1). Moreover, they were also
expressed in lymphatic and vascular endothelia adjacent to the
carcinoma showing strong staining for them (Figure 1). VEGFR-3
was detected in both lymphatic and vascular endothelial cells
adjacent to tumour nests in positive cases (Figure 2). VEGFR-3
staining also highlighted vessel invasion by carcinoma cells
(Figure 2).
Correlation between detection of VEGF-C, VEGF-D and
VEGFR-3, and clinico-pathological factors, and relation
between detections of VEGF-C or VEGF-D and VEGFR-3 in
ovarian carcinomas
When a case with moderate or strong staining was regarded as
positive, 39 (66.1%) and 37 (62.7%) of the 59 ovarian carcinomas
were positive for VEGF-C and VEGF-D, respectively.
The correlation between the presence of VEGF-C, VEGF-D and
VEGFR-3, and clinico-pathological factors in ovarian carcinomas
is displayed in Table 2. The presence of VEGF-C, VEGF-D and
VEGFR-3 had no correlation to histological type, grade, distant
metastasis or age at surgery. Ovarian carcinomas with lymph node
metastasis showed a significantly stronger staining for VEGF-C,
Figure 2 Immunohistochemical staining of VEGFR-3 and VEGF-D in endothelial cells adjacent to carcinoma. (A) VEGFR-3-positive lymphatic and vascular
endothelial cells (scale bar, 25mm). (B) VEGFR-3 staining highlighted vessel invasion by carcinoma cells (arrows) (scale bar, 25mm). VEGF-D-positive
endothelial cells (C) in vessels invaded by ovarian carcinoma was positive for VEGFR-3 (D) (scale bars 25mm). Arrows on each inset show endothelia that
were positive for VEGF-D (C) or VEGFR-3 (D). Asterisks on each inset reveal carcinoma cell (scale bars on inset, 12.5mm).
VEGF-D in epithelial ovarian carcinoma
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British Journal of Cancer (2003) 88(2), 237–244 & 2003 Cancer Research UKVEGF-D and VEGFR-3 than those without (Table 2). Also, the
levels of VEGF-C, VEGF-D and VEGFR-3 proteins significantly
increased according to the presence of peritoneal metastasis
outside the pelvis (Table 2). A significant positive correlation was
found between VEGF-C and VEGF-D detected in carcinoma cells
and VEGFR-3 detected in endothelial cells adjacent to the
carcinoma (Table 2).
Survival of patients with ovarian carcinomas according to
clinico-pathological factors and VEGF-C, VEGF-D or
VEGFR-3 detection
We examined carcinoma-specific survival among patients with
ovarian carcinoma using univariate analysis according to clinico-
pathological factors and the presence of VEGF-C, VEGF-D and
VEGFR-3 (Table 3). The 10-year survival rate of the 22 patients
with VEGF-D-negative carcinoma was 85.1%, whereas that of the
37 patients with VEGF-D-positive carcinoma was 30.2% (Table 3,
log-rank, Po0.002). While the presence of VEGF-C significantly
correlated with poor prognosis (Table 3, log-rank, P¼0.046), that
of VEGFR-3 was not a significant prognostic parameter in ovarian
carcinoma (Table 3, log-rank P¼0.13). Other prognostic factors
with significance in univariate analysis were peritoneal metastasis
outside the pelvis, lymph node metastasis and age at surgery
(Table 3).
We then performed a multivariate regression analysis to
determine the independent value of each parameter predicting
carcinoma-specific survival (Table 4). Using Cox regression
analysis, we examined prognostic parameters of ovarian carcino-
mas that were significant in univariate analysis. The presence of
VEGF-D was an independent prognostic factor for poor survival
(Table 4, relative risk: 8.2, 95% CI: 2.33–83.33). Other independent
prognostic factors related to poor survival were lymph node
metastasis and age at surgery (Table 4).
DISCUSSION
We have investigated the distribution of VEGF-C, VEGF-D and
VEGFR-3 during progression from a benign tumour to carcinoma.
Immunopositivity became more frequent with progression from a
benign tumour to carcinoma (Table 1). Each antigen stained more
intensely in cases of carcinoma than in benign or borderline
tumours (Table 1). Staining was significantly stronger in advanced
disease (Table 2). While VEGF-A is involved in tumour progres-
sion and maintenance, relatively little is known of the physio-
logical role of other members of the VEGF family in tumour
progression. Our previous in situ hybridisation study suggested
that VEGF-B might play a significant role in progression of ovarian
tumours (Sowter et al, 1997). The present immunohistochemical
results suggest a significant role for VEGF-C and VEGF-D in
ovarian tumorigenesis. With regard to the association of VEGFR-3
with tumorigenesis, there have been very few reports to date and
its contribution to tumour progression is less well understood.
While VEGFR-3 expression significantly correlates with tumour
progression in breast carcinoma (Gunningham et al, 2000), no
correlation was found in colon carcinoma (Andre et al, 2000). The
present immunohistochemical results provide evidence for a
possible role for VEGFR-3 in ovarian tumorigenesis.
We have shown that increased levels of VEGF-D protein in
ovarian carcinoma are significantly related to peritoneal metastasis
outside the pelvis and lymph node metastasis (Table 2). Moreover,
increase of VEGF-D protein is independently associated with poor
survival in patients with this disease (Table 4). Two recent studies
on colorectal carcinoma (CRC) reported contradictory results
concerning the relation between VEGF-D detection, clinical
parameter and outcome. White et al (2002) showed that high
levels of VEGF-D were significantly associated with lymph node
involvement and poor survival in CRC, whereas George et al (2001)
found significantly lower levels of VEGF-D in CRC than in normal
Table 2 Relation between detection of VEGF-C, VEGF-D and VEGFR-3 and clinico-pathological factors in ovarian carcinoma
Factors No. of patients
No. (%) of VEGF-C
positive case P-value
No. (%) of VEGF-D
positive case P-value
No. (%) of VEGFR-3
positive case P-value
Peritoneal metastasis outside the pelvis
Negative 39 22 (56.4) 21 (53.8) 20 (51.3)
Positive 20 17 (85.0) 0.03 16 (80.0) 0.04 16 (80.0) 0.03
Lymph node metastasis
Negative 44 25 (56.8) 24 (54.5) 21 (47.7)
Positive 15 14 (93.3) 0.008 13 (86.7) 0.02 15 (100) 0.0001
Distant metastasis
Negative 55 35 (63.6) 34 (61.8) 33 (60.0)
Positive 4 4 (100) NS 3 (75.0) NS 3 (75.0) NS
Age (y)
p60 37 22 (59.5) 22 (59.5) 23 (62.1)
>60 22 17 (77.3) NS 15 (68.2) NS 13 (59.1) NS
Histology type
Serous 32 22 (68.7) 22 (68.7) 21 (65.6)
Nonserous 27 17 (63.0) NS 15 (55.6) NS 15 (55.6) NS
Histological grade
Well 36 22 (61.1) 21 (58.3) 19 (52.8)
Moderate 15 11 (73.3) 10 (66.7) 12 (80.0)
Poor 8 6 (75.0) NS 6 (75.0) NS 5 (62.5) NS
VEGFR-3
Negative 23 11 (47.8) 10 (43.5) F
Positive 36 28 (77.8) 0.02 27 (75.0) 0.02 F
NS=not significant.
VEGF-D in epithelial ovarian carcinoma
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British Journal of Cancer (2003) 88(2), 237–244 & 2003 Cancer Research UKmucosa and no association between the presence of VEGF-D and
lymphatic spread. Similarly, low levels of VEGF-D correlate with
lymph node metastasis in lung adenocarcinoma (Niki et al, 2000),
and head and neck squamous cell carcinoma (O-charoenrat et al,
2001). However, a significant relation of VEGF-D detection with
lymphatic spread has been found in breast carcinoma (Kurebaya-
shi et al, 1999). These discrepancies may depend on differences of
methodology or antibodies used in each experiment, or may be
because of the specific carcinoma explored. Most of these previous
studies lacked survival analysis. The present study is the first
report to show that VEGF-D is an independent prognostic factor in
ovarian carcinomas.
We have also shown a significant association between VEGF-C
detection and peritoneal metastasis outside the pelvis as well as
lymph node metastasis in ovarian carcinoma (Table 2). In
addition, the ovarian carcinoma patients with high levels of
VEGF-C protein had a significantly worse prognosis compared to
those without (Table 3), although the presence of VEGF-C did not
retain significance after multivariate analysis (Table 4). A positive
association of VEGF-C protein levels with lymph node metastasis
has been found in a variety of carcinomas including stomach, lung,
colorectal, oesophageal, prostatic and endometrioid (Tsurusaki
et al, 1999; Yonemura et al, 1999; Akagi et al, 2000; Niki et al, 2000;
Hirai et al, 2001; Kajita et al, 2001; Kitadai et al, 2001). Several
previous studies have shown a prognostic aspect of VEGF-C
detection in carcinoma tissues. Ichikura et al (2001) reported that
high levels of VEGF-C was an independent prognostic determinant
in gastric carcinoma, whereas Kajita et al (2001) found no
independent impact of VEGF-C detection in nonsmall cell lung
carcinoma outcome. Although we could not find prognostic
independence of VEGF-C detected in ovarian carcinoma, to the
best of our knowledge, this is also the first report documenting a
prognostic aspect of VEGF-C expression in this disease.
Recent studies suggest a correlation between the presence of
VEGFR-3 and clinical parameters and prognosis in human
malignancies. While VEGFR-3 protein levels were not related to
lymphatic spread in gastric and breast carcinoma (Yonemura et al,
1999; Jacquemier et al, 2000), VEGFR-3 detection was found to
predict the presence of lymphatic metastases in oral squamous cell
carcinoma (Moriyama et al, 1997). In the present study, we found a
significant correlation between VEGFR-3 expression and lymph
node metastasis (Table 2). However, we did not find that outcome
was predicted by the presence of VEGFR-3 in endothelial cells
adjacent to tumour nests (Table 3), which is consistent with similar
studies in breast, nonsmall cell lung and colorectal carcinoma
(Jacquemier et al, 2000; Kajita et al, 2001; White et al, 2002).
In the present study, a significant positive correlation was found
between VEGF-C or VEGF-D detected in carcinoma cells and
VEGFR-3 detected in endothelial cells adjacent to tumour nests
(Table 2). A significant association between the levels of detection
of VEGF-C and VEGFR-3 has also been found in malignant
mesothelioma, gastric carcinoma and nonsmall cell lung carci-
noma (Ohta et al, 1999; Yonemura et al, 1999; Kajita et al, 2001),
whereas there was no association between VEGF-D and VEGFR-3
detection in colorectal carcinoma (White et al, 2002). The present
result suggests that VEGF-D and VEGF-C secreted by ovarian
carcinoma cells may be able to modulate lymphatic spread and
intraperitoneal tumour dissemination through upregulation of
VEGFR-3 in endothelial cells of both lymphatic and vascular
vessels. We found that VEGFR-3 was expressed not only within
lymphatic but also within vascular vessels neighbouring carcinoma
nests. VEGFR-3 has been proposed to be a specific marker for
lymphatic endothelial cells (Jussila et al, 1998; Breiteneder-Geleff
et al, 1999) and to play a key role in lymphangiogenesis (Jeltsch
et al, 1997). However, a recent study showed that VEGFR-3 is
expressed in the vascular endothelium of breast carcinoma
Table 3 Kaplan–Meier survival analysis: carcinoma-specific survival in
ovarian carcinomas according to clinico-pathological factors and VEGF-C,
VEGF-D or VEGFR-3 detection
Variables
No. of
patients
10-year
survival
rate (%) v
2
Log-rank
P-value
VEGF-C 3.956 0.046
Negative 20 79.2
Positive 39 40.1
VEGF-D 9.365 0.002
Negative 22 85.1
Positive 37 30.2
VEGFR-3 2.282 0.13
Negative 23 69.5
Positive 36 22.7
Peritoneal metastasis outside the pelvis 23.524 o0.0001
Negative 39 75.2
Positive 20 Not reached
Lymph node metastasis 25.372 o0.0001
Negative 44 69.1
Positive 15 9.7
Distant metastasis 1.707 0.19
Negative 55 50
Positive 4 50
Age (y) 4.736 0.03
p60 37 56.2
>60 22 36.1
Histological type 1.789 0.18
Serous 32 31.6
Nonserous 27 63.3
Histological grade 3.669 0.055
Well 36 69.8
Moderate and poor 23 Not reached
Table 4 Determination of independent factors affecting survival using
Cox regression model
Carcinoma-specific survival
Variables Relative risk 95% CI P-value
VEGF-C
Negative 1
Positive 2.7 0.72–37.51 0.101
VEGF-D
Negative 1
Positive 8.2 2.33–83.33 0.004
Peritoneal metastasis outside the pelvis
Negative 1
Positive 2.2 0.66–19.61 0.138
Lymph node metastasis
Negative 1
Positive 5.7 1.44–38.46 0.017
Age (y)
p60 1
>60 12.1 2.72–35.71 0.001
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British Journal of Cancer (2003) 88(2), 237–244 & 2003 Cancer Research UK(Valtola et al, 1999). Moreover, two more recent studies indicated
an association between VEGFR-3 and angiogenesis as well as
lymphangiogenesis. Witmer et al (2001) reported that VEGFR-3
was localised in the cytoplasm and on the cell membrane of
endothelial cells of sprouting blood vessels and sprouting
lymphatic vessels. Niki et al (2001) found that most VEGFR-3
positive vessels detected in invasive lung adenocarcinoma were
blood vessels with only a limited number having the characteristics
of lymphatic vessels.
Both VEGF-C and VEGF-D were detected not only in carcinoma
cells, but also in lymphatic and vascular endothelia adjacent to
carcinoma showing strong positive staining (Figure 1). However,
they were not detected in vessels distant from the carcinoma. This
could simply reflect the expression of VEGF-C and VEGF-D bound
to their receptors. Indeed, most of the VEGF-C- and VEGF-D-
positive vessels adjacent to ovarian carcinoma examined in this
study were also positive for VEGFR-3 (Figure 2). This suggests that
they contribute to the regulation of tumour angiogenesis and
lymphangiogenesis by establishing a paracrine mechanism in
ovarian carcinoma. However, Birner et al (2000) demonstrated that
lymphatic microvessel density did not correlate with the progres-
sion of epithelial ovarian carcinoma. Thus, although we did not
measure microvessel density in this study, it may be necessary in
large scale to elucidate a possible role of VEGFR-3 in lymph-
angiogenesis.
This study clarified that VEGF-C and VEGF-D detected in the
carcinoma and VEGFR-3 detected in adjacent endothelial cells
have a significant impact on lymph node metastases and
intraperitoneal tumour development in ovarian carcinoma. Inter-
estingly, the presence of VEGF-D, but not that of VEGF-C and
VEGFR-3, was found to be an independent prognostic factor in
ovarian carcinoma. A mechanistic explanation for the prognostic
independence of VEGF-D remains unclear. One possible inter-
pretation is that VEGF-D expression is under the control of the
c-fos proto-oncogene product, which is essential for malignant
progression (Orlandini et al, 1996). Recently, high expression of
VEGF-D has been found to correlate with the upregulation of
Fra-1, a member of the AP-1 family of transcription factors
(Debinski et al, 2001). High levels of AP-1 protein including Fra-1
are related to malignant phenotype and to more advanced stages
of disease (Battista et al, 1998; Zoumpourlis et al, 2000).
Collectively, these findings suggest an important role for VEGF-
D in transforming the tumour cells into cells with a more
malignant nature. However, VEGF-D expression did not correlate
with poor-differentiated grade known to possess malignant
phenotype in this study. This discrepancy might be explained
partly by recent report that gene expression patterns in ovarian
carcinomas reflect both morphological features and biological
behaviour, regardless of grade using oligonucleotide microarrays
(Schwartz et al, 2002).
The determination of the presence of VEGF-D in combination
with other prognostic factors may enhance the potential to
prospectively identify ovarian carcinoma patients who are at risk
for poor outcome. Although large-scale studies are necessary to
establish the usefulness of VEGF-D expression as a prognostic
predictor, VEGF-D may be a promising target for antilymphangio-
genic and antiangiogenic therapy in the primary and secondary
chemoprevention of ovarian carcinoma.
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